Isaac Barchas is CEO and co-founder of Research Bridge Partners, a biotechnology accelerator. Barchas built RBP’s team and strategy and co-manages new venture creation and investment activity. At Research Bridge Partners, Barchas has served as founding board member of Tetricus, Eradivir, and MorphImmune and as lead turnaround board member of Novosteo (NASDAQ: QNCX). Barchas is also a managing director of RBP-Catalyst Fund I and Arsenal Bridge Ventures II.
Prior to founding Research Bridge Partners, Barchas led the Austin Technology Incubator. Under Barchas’ leadership, ATI companies raised ~$1B in investor capital. Barchas came to ATI from McKinsey & Co., where he served in the Chicago, Sydney, Auckland, and Dallas offices. Barchas served on the leadership teams of McKinsey’s North American Payor/Provider and global Organization practices. Barchas received his AB from Stanford University and his Master’s and JD degrees from The University of Chicago.
